Results 1 to 10 of about 116,569 (282)

Antisense oligonucleotides in neurological disorders [PDF]

open access: yesTherapeutic Advances in Neurological Disorders, 2018
The introduction of genetics revolutionized the field of neurodegenerative and neuromuscular diseases and has provided considerable insight into the underlying pathomechanisms. Nevertheless, effective treatment options have been limited.
Claudia D. Wurster, Albert C. Ludolph
doaj   +3 more sources

Ultrasmall nanoparticles for co-delivery of antisense oligonucleotides targeting miR-21 and miR-210 to treat glioblastoma [PDF]

open access: yesJournal of Nanobiotechnology
Glioblastoma (GBM) is the most common and aggressive type of brain tumour, with less than 5% of patients surviving more than 5 years. Despite decades of research to understand the underlying pathophysiological causes, it has witnessed very slow progress ...
Ravi Raj Singh   +2 more
doaj   +2 more sources

Tissue pharmacokinetics of antisense oligonucleotides

open access: yesMolecular Therapy: Nucleic Acids
Pharmacokinetics (PK) of antisense oligonucleotides (ASOs) is characterized by rapid distribution from plasma to tissue and slow terminal plasma elimination driven by re-distribution from tissue.
Erica Bäckström   +7 more
doaj   +3 more sources

Antisense oligonucleotides for neurodegeneration [PDF]

open access: yesScience, 2020
Promising clinical results for Huntington's disease give hope for other ...
Leavitt, BR, Tabrizi, SJ
openaire   +4 more sources

Splice-Switching Antisense Oligonucleotides Targeting Extra- and Intracellular Domains of Epidermal Growth Factor Receptor in Cancer Cells

open access: yesBiomedicines, 2023
Cancer is one of the leading causes of death globally. Epidermal growth factor receptor is one of the proteins involved in cancer cell proliferation, differentiation, and invasion. Antisense oligonucleotides are chemical nucleic acids that bind to target
Akilandeswari Ashwini Balachandran   +3 more
doaj   +1 more source

Antisense oligonucleotides: recent progress in the treatment of various diseases

open access: yesBeni-Suef University Journal of Basic and Applied Sciences, 2022
Background Antisense oligonucleotides are a promising novel class of therapeutic agents to treat different diseases in living things. They provide an efficient method for making target-selective agents because they change gene expression sequences ...
Chandravadivelu Gopi   +2 more
doaj   +1 more source

Antisense oligonucleotides [PDF]

open access: yesNeurology Genetics, 2019
There are few disease-modifying therapeutics for neurodegenerative diseases, but successes on the development of antisense oligonucleotide (ASO) therapeutics for spinal muscular atrophy and Duchenne muscular dystrophy predict a robust future for ASOs in medicine.
Eric Vallabh Minikel   +2 more
openaire   +3 more sources

Effect of native gastric mucus on in vivo hybridization therapies directed at Helicobacter pylori [PDF]

open access: yes, 2015
Helicobacter pylori infects more than 50% of the worldwide population. It is mostly found deep in the gastric mucus lining of the stomach, being a major cause of peptic ulcers and gastric adenocarcinoma. To face the increasing resistance of H.
Azevedo, Nuno F   +13 more
core   +15 more sources

NKX2-5 regulates the expression of beta-catenin and GATA4 in ventricular myocytes. [PDF]

open access: yes, 2009
BackgroundThe molecular pathway that controls cardiogenesis is temporally and spatially regulated by master transcriptional regulators such as NKX2-5, Isl1, MEF2C, GATA4, and beta-catenin.
Amini, Fariba   +7 more
core   +18 more sources

An Investigation into the Potential of Targeting Escherichia coli rne mRNA with Locked Nucleic Acid (LNA) Gapmers as an Antibacterial Strategy

open access: yesMolecules, 2021
The increase in antibacterial resistance is a serious challenge for both the health and defence sectors and there is a need for both novel antibacterial targets and antibacterial strategies.
Layla R. Goddard   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy